ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum

argenx SE

25/09/2024 08:58

** Shares in Belgian biotech company Argenx  ARGX.BR  rise
4%, with KBC analysts saying its Vyvgart drug is still the top
contender despite positive trial data from a competitor
    ** Amgen  AMGN.O  on Tuesday reported favourable phase 3
data for its Uplizna drug in treating rare muscle-weakening
disease myasthenia gravis
    ** "We deem the Uplizna dataset to be strong yet somewhat
less compelling than Vyvgart," KBC says
    ** "Vyvgart has shown strong effects already at week 4, and
thereby oversteps the efficacy of Uplizna at week 26," KBC adds
    ** The shares are on track for their best day since Aug. 9
if the gains hold, topping Belgium's blue-chip BEL 20 index
 .BFX 
    ** Including Wednesday's rise, they have gained 42% YTD​

 (Reporting by Dimitri Rhodes)
 ((Dimitri.Rhodes@thomsonreuters.com))